VENUSREM

Venus Remedies Share Price

 
Stock touched all time high

 

Start SIP in VENUSREM

Start SIP
Venus Remedies live price: ₹894.45. It opened at ₹935 vs previous close ₹928; intraday high/low: ₹945/₹881. The 50 & 200 DMA stand at ₹745.80/₹605.92.

Venus Remedies Performance

  • Low
  • ₹881
  • High
  • ₹945
  • 52 Week Low
  • ₹278
  • 52 Week High
  • ₹945
  • Open Price₹935
  • Previous Close₹928
  • Volume78,438
  • 50 DMA₹745.80
  • 100 DMA₹694.80
  • 200 DMA₹605.92

Investment Returns

  • Over 1 Month + 17.41%
  • Over 3 Month + 8.37%
  • Over 6 Month + 97.62%
  • Over 1 Year + 207.64%

Smart Investing Starts Here Start SIP with Venus Remedies for Steady Growth!

Invest Now

Venus Remedies Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 15.7
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 1,196
  • P/B Ratio
  • 1.9
  • Average True Range
  • 49.22
  • EPS
  • 57.09
  • Dividend Yield
  • 0
  • MACD Signal
  • 3.08
  • RSI
  • 67.95
  • MFI
  • 66.13

Venus Remedies Financials

Venus Remedies Technicals

EMA & SMA

Current Price
₹894.45
-33.05 (-3.56%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹770.87
  • 50 Day
  • ₹745.80
  • 100 Day
  • ₹694.80
  • 200 Day
  • ₹605.92

Resistance and Support

906.78 Pivot Speed
  • R3 996.02
  • R2 970.38
  • R1 932.42
  • S1 868.82
  • S2 843.18
  • S3 805.22

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Venus Remedies has an operating revenue of Rs. 699.88 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 11% is healthy, ROE of 8% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 15% and 49% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 10% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 71 which is a FAIR score but needs to improve its earnings, a RS Rating of 96 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 51 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Venus Remedies Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-29 Quarterly Results & Others To consider other business matters.
2025-11-10 Quarterly Results
2025-08-01 Quarterly Results
2025-07-08 Others Inter-alia, to consider 1. Notice of 36th Annual General Meeting. 2. Boards Report for Financial Year 2024-2025. 3. Other business matters.
2025-05-26 Audited Results

Venus Remedies F&O

Venus Remedies Shareholding Pattern

41.76%
2.25%
45.16%
10.83%

About Venus Remedies

  • NSE Symbol
  • VENUSREM
  • BSE Symbol
  • 526953
  • Chairman & Managing Director
  • Mr. Pawan Chaudhary
  • ISIN
  • INE411B01019

Similar Stocks to Venus Remedies

Venus Remedies FAQs

Venus Remedies share price is ₹894 As on 13 March, 2026 | 22:13

The Market Cap of Venus Remedies is ₹1195.6 Cr As on 13 March, 2026 | 22:13

The P/E ratio of Venus Remedies is 15.7 As on 13 March, 2026 | 22:13

The PB ratio of Venus Remedies is 1.9 As on 13 March, 2026 | 22:13

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23